EP1109896A4 - Formulations d'adenovirus pour therapie genique - Google Patents

Formulations d'adenovirus pour therapie genique

Info

Publication number
EP1109896A4
EP1109896A4 EP99941147A EP99941147A EP1109896A4 EP 1109896 A4 EP1109896 A4 EP 1109896A4 EP 99941147 A EP99941147 A EP 99941147A EP 99941147 A EP99941147 A EP 99941147A EP 1109896 A4 EP1109896 A4 EP 1109896A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
adenovirus formulations
adenovirus
formulations
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99941147A
Other languages
German (de)
English (en)
Other versions
EP1109896A1 (fr
Inventor
Shian-Jiun Shih
Karen R Mcglennon
Dewey Moody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of EP1109896A1 publication Critical patent/EP1109896A1/fr
Publication of EP1109896A4 publication Critical patent/EP1109896A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP99941147A 1998-08-14 1999-08-13 Formulations d'adenovirus pour therapie genique Withdrawn EP1109896A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9660098P 1998-08-14 1998-08-14
US96600P 1998-08-14
PCT/US1999/018515 WO2000009675A1 (fr) 1998-08-14 1999-08-13 Formulations d'adenovirus pour therapie genique

Publications (2)

Publication Number Publication Date
EP1109896A1 EP1109896A1 (fr) 2001-06-27
EP1109896A4 true EP1109896A4 (fr) 2005-11-02

Family

ID=22258141

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99941147A Withdrawn EP1109896A4 (fr) 1998-08-14 1999-08-13 Formulations d'adenovirus pour therapie genique

Country Status (6)

Country Link
EP (1) EP1109896A4 (fr)
JP (1) JP2003528029A (fr)
AU (1) AU748523B2 (fr)
CA (1) CA2340682A1 (fr)
MX (1) MXPA01001727A (fr)
WO (1) WO2000009675A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284287A4 (fr) * 2000-05-10 2004-10-13 Mitsubishi Pharma Corp Procede de preparation de vecteur de virus
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
JP2005532036A (ja) 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005115477A2 (fr) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Conjugues de ribonuclease non naturelle utilises en tant qu'agents cytotoxiques
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
CA2612021A1 (fr) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions et procedes de traitement et de diagnostic de cancer
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US8652467B2 (en) 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628116A1 (fr) 2005-10-31 2007-12-13 Oncomed Pharmaceuticals, Inc. Compositions et procedes de diagnostic et de traitement du cancer
JP2009541333A (ja) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
EP2049151A4 (fr) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Méthodes et compositions pour le traitement du cancer
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
CA2692441C (fr) 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Fusions de gene solute carrier family 45 member 3 (slc45a3) et d'un genede la famille ets dans le cancer de la prostate
US20090047269A1 (en) 2007-08-16 2009-02-19 The Regents Of The University Of Michigan Metabolomic cancer targets
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
US8193151B2 (en) 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
WO2010037041A2 (fr) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
EP2334695B1 (fr) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Ribonucléases thérapeutiques
JP2012514475A (ja) 2009-01-09 2012-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌における再現性の遺伝子融合物
WO2010142017A1 (fr) * 2009-06-09 2010-12-16 Defyrus, Inc . Administration d'interféron pour une prophylaxie contre une infection pathogène ou un traitement d'une infection pathogène
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011116209A2 (fr) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Utilisation d'épitopes de phage à des fins de profilage de la réponse immunitaire
CA2794674A1 (fr) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Agents de liaison aux recepteurs frizzled et leurs utilisations
WO2013001372A2 (fr) 2011-06-30 2013-01-03 University Of Oslo Procédés et compositions pour inhiber l'activation des lymphocytes t régulateurs
US10980879B2 (en) 2011-07-06 2021-04-20 Sykehuset Sørlandet Hf EGFR targeted therapy
WO2013119880A1 (fr) 2012-02-07 2013-08-15 Global Bio Therapeutics Usa, Inc. Procédé compartimenté d'administration d'acide nucléique et ses compositions et utilisations
WO2014066328A1 (fr) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de tumeurs neuro-endocrines à l'aide d'agents liants de parcours wnt
AU2013362134B2 (en) 2012-12-21 2018-07-05 Sykehuset Sorlandet Hf EGFR targeted therapy of neurological disorders and pain
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2017172772A1 (fr) 2016-03-28 2017-10-05 Dimension Therapeutics Procédés d'inactivation thermique d'adénovirus
WO2018013509A1 (fr) 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et méthodes pour diagnostiquer et traiter des arythmies
US11241436B2 (en) 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
AU2018372906A1 (en) 2017-11-22 2020-06-11 The Regents Of The University Of Michigan Compositions and methods for treating cancer
CN110960484A (zh) * 2019-11-05 2020-04-07 深圳市天达康基因工程有限公司 一种重组腺病毒缓释制剂、制备方法及其应用
CN110772477A (zh) * 2019-11-05 2020-02-11 深圳市天达康基因工程有限公司 一种重组腺病毒缓释水凝胶、制备方法及其应用
JP2023537818A (ja) 2020-08-11 2023-09-06 マスキュロスケレタル トランスプラント ファウンデーション 胎盤由来組成物を用いた心疾患を治療するための方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
WO1996032116A1 (fr) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Compositions et procedes de liberation d'acide nucleique dans les poumons
EP0764446A2 (fr) * 1995-09-21 1997-03-26 Bayer Corporation Vaccin adjuvé pratiquement exempt d'albumine non-hÔte

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
DE3919393A1 (de) * 1989-06-14 1990-12-20 Hoechst Ag Verfahren zur stabilisierung von auf festphasen immobilisierten biologisch aktiven substanzen
JP3770333B2 (ja) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
WO1996032116A1 (fr) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Compositions et procedes de liberation d'acide nucleique dans les poumons
EP0764446A2 (fr) * 1995-09-21 1997-03-26 Bayer Corporation Vaccin adjuvé pratiquement exempt d'albumine non-hÔte

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CROYLE M A ET AL: "FACTORS THAT INFLUENCE STABILITY OF RECOMBINANT ADENOVIRAL PREPARATION FOR HUMAN GENE THERAPY", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, vol. 3, no. 3, August 1998 (1998-08-01), pages 373 - 383, XP000881617, ISSN: 1083-7450 *
KANEGAE Y ET AL: "A SIMPLE AND EFFICIENT METHOD FOR PURIFICATION OF INFECTIOUS RECOMBINANT ADENOVIRUS", JAPANESE JOURNAL OF MEDICAL SCIENCE AND BIOLOGY, TOKYO, JP, vol. 47, no. 3, June 1994 (1994-06-01), pages 157 - 166, XP000876518, ISSN: 0021-5112 *
KOJIMA ET AL: "ADENOVIRUS MEDIATED TRANSDUCTION OF NEUROTROPHIC FACTOR GENE(S) AS A NEUROPROTECTIVE THERAPY FOR NEURODEGENERATIVE DISEASES", IKAGAKU OYO KENKYU ZAIDAN KENKYU HOKOKU, vol. 15, 1996, pages 230 - 234, XP008052124 *
See also references of WO0009675A1 *

Also Published As

Publication number Publication date
AU5485899A (en) 2000-03-06
JP2003528029A (ja) 2003-09-24
WO2000009675A9 (fr) 2000-08-03
CA2340682A1 (fr) 2000-02-24
EP1109896A1 (fr) 2001-06-27
MXPA01001727A (es) 2001-11-27
AU748523B2 (en) 2002-06-06
WO2000009675A1 (fr) 2000-02-24

Similar Documents

Publication Publication Date Title
EP1109896A4 (fr) Formulations d'adenovirus pour therapie genique
SG79255A1 (en) Pharmaceutical formulations
PL343021A1 (en) Formulations
GB9622500D0 (en) Therapeutic gene
SG77243A1 (en) Ziprasidone formulations
IL133010A0 (en) Alternatively targeted adenovirus
GB2323531B (en) Therapeutic formulations
EP1077996A4 (fr) GENE EDG3sb HUMAIN
HUP0104046A3 (en) Adenovirus-mediated gene therapy
GB9816556D0 (en) Therapy
EP1078639A4 (fr) Preparations geniques stables
GB9806312D0 (en) Novel formulations
GB0025890D0 (en) Gene therapy
GB9815001D0 (en) Formulations
GB9815002D0 (en) Formulations
EP1084236A4 (fr) Nouveaux vecteurs adenoviraux utilises en therapie genique
GB9900009D0 (en) Gene therapy
AU3036197A (en) Adenovirus vectors for gene therapy
GB0406539D0 (en) Gene therapy
GB9810181D0 (en) Novel formulations
GB9806039D0 (en) Therapy
GB9709417D0 (en) Therapeutic formulations
GB9920837D0 (en) Gene therapy
GB9910587D0 (en) Gene therapy
GB9720228D0 (en) Parasiticidal formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010309

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20010309;LV;MK;RO;SI PAYMENT 20010309

A4 Supplementary search report drawn up and despatched

Effective date: 20050921

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS INC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AVENTIS PHARMACEUTICALS, INC.

17Q First examination report despatched

Effective date: 20060327

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/861 20060101ALI20070413BHEP

Ipc: C07H 21/04 20060101ALI20070413BHEP

Ipc: A61K 35/00 20060101ALI20070413BHEP

Ipc: A61K 48/00 20060101ALI20070413BHEP

Ipc: C12N 15/63 20060101ALI20070413BHEP

Ipc: C12N 15/00 20060101AFI20070413BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080219